An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation
- Lining Zhu
- Zhihui Zhao
- Yanzhang Wei
- William Marcotte
- Thomas E. Wagner
- Xianzhong Yu
- Published online on: May 8, 2012 https://doi.org/10.3892/ijo.2012.1466
- Pages: 661-669
As an integral part of the innate immune system, natural killer (NK) cells respond rapidly to infectious diseases and malignant transformation to restrict the dissemination of diseases and to elicit the long-lasting, antigen-specific adaptive immune reactions (1). Numerous studies have illustrated that NK cells can effectively control tumor growth through perforin (2) and cytokines (3). The critical role of NK cells in anti-tumor immunity has been further demonstrated by clinical studies showing that patients with dysfunctional NK cells have an increased risk of developing leukemia (4).
Normal NK cells are usually not found in the cell cycle; they are found only in response to infection from certain pathogens or to the stimulation with high doses of appropriate cytokines [type I interferons (IFNs), interleukin (IL)-2, IL-12 or IL-15] (5). The early pioneering study on lymphokine-activated killer cell-based immunotherapy by Rosenberg was based on this protocol (6). Current techniques for activating NK cells are all based on cytokines, usually with high doses which are not well-tolerated by the host. IL-2 is known as the growth factor for both T lymphocytes and NK cells, and potentially enhances the cytotoxicity of these cells as well. Resting NK cells from humans and mice respond readily to recombinant IL-2 (rIL-2) stimulation, without the help of accessory cells and co-factors (7). It has been suggested that the in vivo survival, tumor localization, and consequently, the antitumor effect of the activated NK (A-NK) cells are strongly dependent on the continuous support of relatively high doses of exogenous IL-2 (8). It has been shown that optimal tumor localization and antitumor activity of the adoptively transferred NK cells are difficult to achieve even when IL-2 was systemically administered every 4 h for 3 consecutive days due to the short in vivo half-life of IL-2 (∼6.9 min) (9). When long-lived (0.5 to 4 h) polyethylene glycol-conjugated IL-2 (PEG-IL-2) was used, tumor localization and antitumor activity were substantially improved (10). Other cytokines, such as IL-12 (11), IL-15 and IL-21, which strongly augment NK cell proliferation and effector functions, have also been used to substitute for IL-2. However, all the cytokines systemically used in vivo have been associated with dose-related toxicity (12). It is clear that an alternative has to be found to circumvent the demand of A-NK cells for exogenous IL-2 to sustain their activities before adoptive NK cell transfer can be clinically feasible.
The adenovirus transduction of A-NK cells with IL-12 not only can enhance their antitumor effectiveness but can also reduce their reliance on systemically administered IL-2 (8). However, the expression of IL-12 in NK cells may still have the potential to cause a systemic IL-12 effect. In a mouse B16 tumor model, the direct delivery of IL-12 to the tumor site maintained its anticancer activity but avoided much of the toxic side-effects (13). The co-transfection of tumor cells with GPI-anchored IL-2 and IL-12 has been shown to synergistically enhance the anti-tumor effect and to have less adverse effects (14). It has also been reported that endoplasmic reticulum-restricted IL-2 offers autocrine growth stimulation to NK-92 cells (15). In this study, we designed a fusion gene between mouse sonic hedgehog (Hh) C-terminal (Shh-C) auto-processing domain and IL-12 (IL-12/Shh-C) as a self-supporting autocrine system to reduce or eliminate the dependency of NK cells on exogenous cytokines and sustain their activated status.
Hh family proteins have been shown to play essential roles in cell fate specification during development. As morphogens, they are produced from localized sites and spread through the extracellular matrix to form a gradient and determine cell fates through multiple regulations in a concentration-dependent manner (16–21). The Hh precursor protein undergoes internal proteolysis between Gly-Cys residues to confer cholesterol modification at its carboxy terminus and palmitoylation modification at its amino terminus (22). The cholesterol moiety serves as a membrane-anchorage to restrict long-range signaling and unregulated spreading, thus increasing local Shh concentration (23). It has been demonstrated that Shh-C can direct green fluorescent protein (GFP) to the cell membrane with a cholesterol tail attached (24). The results from the present study show that mouse NK cells transduced with lentiviruses encoding this IL-12/Shh-C fusion gene have significantly reduced dependency on IL-2 in vitro. Also, prolonged survival was observed when ex vivo A-NK cells transduced with IL-12/Shh-C lentivirus were adoptively transferred to B16 melanoma tumor-bearing mice.
Materials and methods
Fusion gene construction and lentivirus production
Eleven-day mouse embryo total RNA was purchased from Clontech. cDNA was generated by reverse transcription with a RetroScript kit (Ambion). Mouse Shh-C was PCR-amplified and cloned into the pCR2.1 vector (Invitrogen). Mouse mIL-12 fragment without stop codon was amplified with PCR using the pORF-mIL-12 plasmid (Invivogen) as the template. The enhanced GFP (EGFP) fragment without stop codon was PCR-amplified with pIRES-EGFP (Clontech) as the template. Both mIL-12 and EGFP fragments were subcloned into pCDH-EF1-MCS (System Biosciences) to construct the plasmid pCDH-EGFP and pCDH-fusion-IL-12. pCDH-ORF-mIL-12 was generated by ligation of pCDH-EF1-MCS digested with SwaI and pORF-mIL-12 treated with SwaI and EcoRV.
The calcium phosphate transfection method was used in lentivirus production. 293TN cells were seeded at the density of 7×106 cells per T-150 flask one day before transfection without antibiotics. Different lentiviral expression vectors (40 μg) (pCDH-EGFP, pCDH-ORF-mIL-12 and pCDH-fusion IL-12) were mixed with pMDLg/pRRE, pRSV-Rev and pMD2.G (Addgene) and used for co-transfection of 293TN cells. Forty-eight hours post-transfection, supernatant containing recombinant lentiviral particles was clarified with 0.45 μm filter (Corning) and stored at −80°C. Lentivirus was titered by CHO cell transduction. Briefly, 1×105 CHO cells were plated into 24-well plate and lentivirus was added with various dilution factors of 10−2 to 10−1 in the presence of 8 μg/ml of polybrene (Sigma-Aldrich). After 1-h centrifugation at 1,200 × g, the cells were incubated for 5 h at 37°C and 5% CO2. Four days after transduction, biological titer was calculated by the following equation as previously described (27): transduction unit (TU/ml) = (% of GFP- or IL-12 positive cells × number of cells at time of transduction) × dilution factor/(100× volume of lentivirus added).
Mice and tumor cell lines
Female C57BL/6 mice and congenic B6.PL-Thy1a/CyJ mice, purchased from Jackson Laboratory, at age 8–20 weeks were used for the present study, and all experiments were carried out with approval from the Institutional Animal Care and Use Committee. The murine melonoma cell line, B16, was obtained from ATCC. B16 cells were maintained in RPMI-1640 (Hyclone) with 10% heat-inactivated fetal bovine serum (FBS), 2 mM of glutamine and antibiotics.
NK cell isolation and lentiviral transduction
Congenic B6.PL-Thy1a/CyJ mice were sacrificed and spleen tissues were homogenized by grinding the tissues with 2 frosted glass slides. After filtering through a cell strainer of 40 μm (BD Biosciences) to obtain a single cell suspension, spleen cell were centrifuged at 300 × g for 15 min. Erythrocytes were lysed by ACK lysing buffer (Lonza). The splenic lymphocytes were then subjected to magnetic labeling and separation by using a Natural Killer Cell Isolation kit (Miltenyi Biotec). The purity of freshly isolated NK cells from the spleen was >90% NK1.1+, <6% CD3+. NK cells were cultured in RPMI-1640 medium (Hyclone) supplemented with 10% heat-inactivated FBS (Hyclone), 50 μM β-mercaptoethanol, 2 mM glutamine, and 1X non-essential amino acids. For activation and expansion purposes, 6,000 IU/ml of recombinant human IL-2 (rhIL-2) (Peprotech) was added every other day. Seven-day rhIL-2-stimulated NK cells were plated into 48-well plates at 2×105 cells/250 μl per well. NK cells were transduced at 1 MOI in the presence of 5 μg/ml polybrene (Sigma-Aldrich) by centrifugation at 1,200 × g for 1 h. After centrifugation, transduced NK cells were incubated at 37°C and 5% CO2 for an additional 4 h then replaced with complete culture medim. The following day, lentiviral transduction was repeated on the transduced NK cells.
NK cell proliferation assay
NK cells were transduced with EGFP/Shh-C, IL-12 or IL-12/Shh-C lentiviruses at an MOI of 1 on both days 7 and 8 after isolation. Three days after double transduction, 15,000 NKEGFP/Shh-C, NKIL-12 and NKIL-12/Shh-C cells were plated per well in 96-well plates with 100 μl of culture medium, supported with 0, 60, 600 and 6,000 IU/ml of IL-2. IL-2 was added every other day. Proliferation assays were performed 24, 48, 72 and 96 h after plating. AlamarBlue (Invitrogen) reagent was added in an amount equal to 10% of the culture volume. After being cultured for 4.5 h at 37°C/5% CO2, the absorbance was measured at a wavelength of 560 nm with a reference of 620 nm. The cell numbers were determined by using a standard curve. All samples were run in triplicate.
Analysis of NK cell markers by flow cytometry
EGFP expression was directly detected by comparing transduced versus non-transduced NK cells. Antibodies for surface marker analysis of NK cells for anti-NK1.1, CD3, CD25 and CD11b were all from BD Pharmingen. For intracellular staining, anti-IL-12 p40, perforin and ganzyme B were obtained from eBioscience. Prior to staining with antibodies, mouse BD Fc Block (BD Biosciences) was used to prevent non-specific binding. All samples were fixed with BD Cytofix™ Fixation Buffer (BD Biosciences) and then stored in phosphate-buffered saline supplemented with 2% FBS and 0.2% sodium azide (Sigma). For intracellular staining, samples were fixed then permeabilized with BD Cytoperm™ Permeabilization Buffer (BD Biosciences) prior to antibody staining. A minimum of 15,000 cells were used in all samples. Data acquisition was performed on a Guava EasyCyte Mini system (Guava Technologies) and analyzed by FACS Express 2 software. Data obtained from quadrant gating were compared to the non-transduced control group.
Cytokine production analysis
Supernatants from overnight NK cell cultures 7 days after lentiviral infection and serum from experimental mice were used to determine IFN-γ, IL-12 and tumor necrosis factor-α (TNF-α) levels. Mice serum from each group was collected from the tail vein at 3, 7 and 14 days after the adoptive transfer of NK cells. The mouse IFN-γ ELISA Ready-SET-Go kit, the mouse IL-12/IL-23 total p40 ELISA Ready-SET-Go kit and the mouse TNF-α ELISA Ready-SET-Go kit (eBioscience) were used according to manufacturer’s instructions.
NK cell cytotoxicity assay
Mouse lymphoma YAC-1 cells were used as the target and stained with 0.5 μM Guava CFSE (Guava Technologies) per 2.5×106 cells. Triplicate wells of NK cells were mixed with YAC-1 cells in 96-well round bottom plates to yield effector cell to target cell (E:T) ratios of 2:1, 1:1, 0.5:1 and 0.2:1. The plates were centrifuged at 50 × g for 2 min prior to 4-h incubation at 37°C and 5% CO2. Subsequently, 50 μl of Guava Express 7-AAD (Guava Technologies) per 1×105 cells were added into each well. Five thousand events were acquired for each sample. YAC-1 cells only were used as the control for spontaneous cell death. The percentage of NK cell cytotoxicity was calculated using the following equation: percentage of specific lysis = (% dead targets − % spontaneous dead targets) × 100/(100 − % spontaneous dead targets).
Adoptive transfer of NK cells
C57BL/6 mice received 3.75×105 B16 melanoma tumor cells intravenously (i.v.) to establish pulmonary metastases. Three days later, 5×106 NKEGFP/Shh-C cells, NKIL-12 cells and NKIL-12/Shh-C cells were injected via the lateral tail vein without IL-2 administration.
Analysis of tumor infiltration by NK cells in vivo
Seventy-two hours after adoptive transfer, lung tissues obtained from mice were fresh frozen at −80°C and were then sectioned into 8-μm tissue slides. After fixing in 4% paraformaldehyde, tissues were stained with FITC-conjugated anti-Thy 1.1 Ab (BD Pharmingen) at a 1:200 dilution for 30 min at room temperature. FITC-conjugated IgG2a (BD Pharmingen) was used as an isotype control. A fluorescent microscope was used to obtain images.
Two-tailed, unpaired Student’s t-tests were used. For survival experiments, data were analyzed by the Kaplan-Meier method.
Fusion gene construction and expression
To construct the EGFP/Shh-C and murine IL-12/Shh-C fusion genes, the N-terminal domain of the mouse sonic Hh gene was replaced with EGFP or murine IL-12 (with signal peptides deleted), leaving the conserved cleavage-processing motif, SGGCF, intact. The fusion genes were then cloned into lentiviral expression vectors (Fig. 1A). The fusion genes were successfully expressed and processed in 293TN cells as expected. As shown in Fig. 1B, EGFP was concentrated around the periphery of cells forming fluorescent holo-circles, indicating that the EGFP fusion protein was successfully processed and tethered on the cell membrane. In Fig. 1C, fusion EGFP (52 kDa), processed EGFP (27 kDa), fusion IL-12 (95 kDa) and processed IL-12 (70 kDa) were all detected by western blot analysis.
Schematic representation of (A) the cloning strategy and (B) EGFP fusion gene expression in 293TN cells. (C) Both EGFP and murine IL-12 (mIL-12) fusion proteins were processed correctly as shown by western blot analysis. EGFP/Shh-C fusion protein was shown as a 52-kDa band and processed EGFP as a 27-kDa band. For mIL-12/Shh-C fusion, the band size was 95 kDa and the processed mIL-12 was a 70-kDa band. mShh-C, mouse Shh-C.
NK cell transduction by fusion gene recombinant lentiviruses
NK cells were doubly-transduced with EGFP/Shh-C, IL-12 or IL-12/Shh-C recombinant lentiviruses at a MOI of 1 on both days 7 and 8 after in vitro culture. On days 3, 5, 7 and 10 after the second transduction, the transduction rates were assayed with FACS analysis. Cell numbers were determined by trypan blue exclusion assay. All 3 recombinant lentiviruses had similar transduction rates (∼30%) on day 10 after the second transduction (Fig. 2A). However, NK cells transduced with IL-12 and IL-12/Shh-C recombinant lentiviruses had higher survival/proliferation rates resulting in significantly higher cell numbers (Fig. 2B).
NK cells were doubly-transduced with EGFP/Shh-C, IL-12, or IL-12/Shh-C lentiviruses at an MOI of 1 on days 7 and 8 after in vitro culture. On days 3, 5, 7 and 10 after the second transduction, the transduction rates were analyzed with FACS for the expression of EGFP and mIL-12 (p40). Cell numbers were determined by trypan blue exclusion assay. (A) Transduction rate. (B) Cell numbers.
IL-12 and IL-12/Shh-C fusion proteins enhance NK cell proliferation in vitro
NK cells untransduced (NKUN) or transduced with different recombinant lentiviruses were plated at a concentration of 15,000 cells/well in a 96-well plate and cultured with different concentrations of IL-2. NKIL-12/Shh-C cells had a substantially faster growth rate compared to NKUN cells and NKEGFP/Shh-C cells; even when IL-2 was absent, NKIL-12/Shh-C cells showed an apparent advantage in expansion compared to NKUN cells and NKEGFP/Shh-C cells at 24 and 96 h after plating (Fig. 3A–D). However, IL-12 cannot be the sole driving force for NK cell survival in the long-term cultures. The effect of IL-12 was most significant when IL-2 was added at low or medium levels (Fig. 3A–D). NKIL-12/Shh-C cells, when given <10-fold addition of IL-2, reached the same cell numbers as NKEGFP/Shh-C cells in most cases.
Proliferation of NKEGFP/Shh-C, NKIL-12 and NKIL-12/Shh-C cells in the presence of different concentrations of IL-2. (A–D) End-point data following 24, 48, 72 and 96 h of culture.
Cytotoxicity of NK cells significantly increased after lentivirus infection
Mouse lymphoma YAC-1 cells were used as the target and stained with 0.5 μM Guava CFSE (Guava Technologies) per 2.5×106 cells. NK cells were mixed with YAC-1 cells in 96-well round bottom plates to yield E:T ratios of 2:1, 1:1, 0.5:1 and 0.2:1. Five days after double transduction, statistically significant differences between the cytotoxicities of NKIL-12/Shh-C and NKIL-12 cells were observed at E:T ratios of 1:1 (p=0.00017) and 2:1 (p=0.02152), as shown in Fig. 4A. Additionally, NKUN cells had a significantly lower cytotoxicity than NKIL-12/Shh-C cells at E:T ratios of 0.5:1 (p=0.00413) and 1:1 (p=0.00026). Furthermore, 7 days after double transduction, significantly elevated cytotoxicities of NKIL-12/Shh-C cells were observed compared to NKUN cells at all E:T ratios, as shown in Fig. 4B. NKIL-12 cells showed enhanced cytotoxicity at an E:T ratio of 1:1 and 2:1 only, in comparison to the effect of NKUN cells.
Cytotoxicity of NKUN, NKIL-12 and NKIL-12/Shh-C cells. After 7 days of in vitro culture, NK cells were doubly-transduced (on days 7 and 8). Five and 7 days after the second transduction, NK cells were mixed with CFSE-coated YAC-1 cells at ratios of 2:1, 1:1, 0.5:1 and 0.2:1 and incubated for 4 h before the addition of 7-AAD. The specific lysis of YAC-1 cells measured by FACS is presented as a percentage. The data represent the averages of 3 independent experiments (*p<0.05; **p<0.01; ***p<0.001).
Phenotypic characterization of recombinant lentivirus-infected NK cells
The percentage of the Mac-1-positive subpopulation in lentivirus-transduced NK cells was significantly higher than that of untransduced NK cells. Statistical analysis showed that NKIL-12/Shh-C cells had insignificantly less Mac-1hi population compared with NKUN cells and NKEGFP/Shh-C cells at 7 days after lentivirus double transduction. On day 9, NKIL-12/Shh-C cells had considerably more Mac-1hi cells than NKUN cells (p=0.00515) (Fig. 5A). For CD25, all the recombinant lentivirus-transduced NK cells showed significantly higher expression levels compared to the untransduced NK cells on both days 7 and 9 after transduction. NKIL-12/Shh-C cells had significantly lower CD25 expression compared to the NKIL-12 and NKEGFP/Shh-C cells (Fig. 5B). Perforin and granzyme B levels were also significantly higher in all lentivirus-transduced cells; however, granzyme B expression in NKIL-12/Shh-C cells was significantly lower than that in NKIL-12 cells (p=0.01349) or NKEGFP/Shh-C cells (p=0.01816). Additionally, significantly lower perforin production was observed in NKIL-12/Shh-C cells when compared to NKIL-12 cells (p=0.04784) (Fig. 5C and D).
Phenotypic characterization of different lentivirus-transduced NK cells. NK cells were doubly-transduced on days 7 and 8 of in vitro culture. Seven and 9 days after lentivirus transduction, surface markers (Mac-1 and CD25) and intracellular markers (perforin and granzyme B) were analyzed by flow cytometry.
Enhanced IFN-γ and IL-12 production by IL-12/Shh-C-infected NK cells
The cell culture supernatants were collected on the 5th and 7th day after double transduction and used for the measurements of IFN-γ and IL-12 by ELISA. As shown in Fig. 6A and B, NKIL-12/Shh-C cells secreted significantly higher amounts of IFN-γ on day 5 (p=0.00240) and even higher on day 7 (p=0.00121) than those secreted by NKIL-12 cells. In addition, the IFN-γ yield of NKIL-12/Shh-C cells was also considerably higher than that of NKEGFP/Shh-C cells on both days (p<0.001). The production of IL-12 was substantially higher by NKIL-12/Shh-C cells compared to that by NKIL-12 cells at 7 days after double transduction (p=0.01186). NKEGFP/Shh-C cells released significantly less IL-12 than NKIL-12/Shh-C on both days (p<0.001).
IFN-γ and IL-12 production of NKEGFP/Shh-C, NKIL-12 and NKIL-12/Shh-C cells. After 7 days of in vitro culture, NK cells were doubly-transduced on days 7 and 8 after in vitro culture. Cells were then cultured in the presence of 6,000 IU/ml of IL-2 for (A and C) 5 days or (B and D) 7 days. After another 36 h of culture, supernatant was collected from both cultures and cytokines were measured by ELISA. Results represent the means of 3 replicates ± SD (*p<0.05; **p<0.01; ***p<0.001).
Elevated plasma cytokine secretion in mice receiving adoptively transferred A-NK cells
Five million transduced or non-transduced NK cells from B6.PL-Thy1a/CyJ mice were adoptively transferred into C57BL/6 mice i.v. challenged with B16 melanoma tumor cells 3 days earlier. Serum samples from mouse tail veins were collected on days 3, 7 and 14 after adoptive transfer. Mice which had received NKIL-12/Shh-C cells showed significantly higher levels of TNF-α on days 3 (p=0.04410), 7 (p=0.03010) and 14 (p=0.00880) compared to the B16 only group, as shown in Fig. 7A. At 14 days after adoptive transfer, only mice which had received NKIL-12/Shh-C cells showed a detectable level of IFN-γ (Fig. 7B). The IL-12 level was significantly higher on day 7 (p=0.01898) in the mice which had received NKIL-12/Shh-C cells compared with the mice which had received NKEGFP/Shh-C cells (Fig. 7B and C).
Cytokine levels in serum of B16 tumor-bearing mice which had received adoptively-transferred NK cells. C57BL/6 mice were injected with 3.75×105 B16 cells intravenously. Three days later, 5×106 NKEGFP/Shh-C, NKIL-12 and NKIL-12/Shh-C cells were injected via the lateral tail vein without systemic IL-2 administration. Serum samples were collected from tails on days 3, 7 and 14 after adoptive NK cell transfer. Cytokine levels were determined by ELISA. Results represent the means ± SD of 3 replicates (*p<0.05; **p<0.01; ***p<0.001).
Adoptively transferred NK cells infiltrate into lung tissue and prolong the survival time of tumor-bearing mice
Five million transduced or non-transduced NK cells from B6.PL-Thy1a/CyJ mice were adoptively transferred into C57BL/6 mice i.v. challenged with B16 melanoma tumor cells 3 or 10 days earlier without IL-2 systemic administration. Tumor-bearing mice which had received NKEGFP/Shh-C, NKIL-12 and NKIL-12/Shh-C cells all resulted in significantly higher overall survival rates than those of the B16 only mice (p=0.0179, p=0.0023 and p=0.0052, respectively; Fig. 8A). In addition, mice which had received NKIL-12 and NKIL-12/Shh-C cells showed significantly prolonged survival times than mice which had received NKEGFP/Shh-C cells (p=0.0116 and p=0.0067, respectively).
In vivo effects of lentivirus-transduced NK cells on B16 tumor-bearing mice. (A) Four groups (n=5) of C57BL/6 mice were intravenously injected with 3.75×105 B16 cells. Five million NKEGFP/Shh-C, NKIL-12 and NKIL-12/Shh-C cells per mouse were injected via the lateral tail vein in 3 different groups 3 days later. Mice survival data were plotted using the Kaplan-Meier method and significant differences were determined by the log-rank test. (B) Total body weight loss of tumor-bearing mice with NK cell adoptive transfer. (C) In vivo lung tissue infiltration by adoptively-transferred NKEGFP/Shh-C, NKIL-12 and NKIL-12/Shh-C cells. Lung tissues were retrieved and sectioned 72 h after NK cell adoptive transfer. Donor NK cells were distinguished from recipients by staining with FITC-conjugated anti-mouse Thy 1.1 antibody.
The localization of adoptively transferred NK cells in lung tissues with 3-day metastasized B16 tumor cells was examined at 72 h after adoptive transfer. Though no exogenous IL-2 injection was given, all groups of donor NK cells were found to be infiltrated into the deep lung tissues (Fig. 8B). More NKIL-12/Shh-C cells were accumulated in the lung tissue indicated by the bigger and brighter fluorescent dots. However, when the late tumor model (10-day) was examined, donor NK cells were found to be difficult to target in the deep lung tissues (Fig. 8C).
The immunogenicity of tumor cells is frequently suppressed by the down-regulation of major histocompatibility complex (MHC)-I and -II expression (25). On the contrary, the NK cell-mediated innate immune response does not require MHC for antigen presentation (26). Therefore, anti-tumor immune responses from NK cells would potentially be a great alternative to T cell-mediated immunotherapy for malignant tumors.
Two different approaches for the therapeutic use of NK cells have been exploited, including endogenous NK cell activation and adoptive transfer of in vitro activated autologous NK cells (27). For adoptive transfer, various animal studies have proven that autologous NK cell transfer is effective in tumor therapy (28). However, clinical trials have failed to meet the high expectations (29). One important contributing factor to the poor outcome in a clinical setting is the severe side-effects caused by IL-2 (30), which needs to be administered in very high doses to patients to ensure the survival and sustained activation of IL-2-A-NK cells. IL-12 has been shown to enhance the antitumor activity of NK cells while reducing their dependency on IL-2 (8). A fusion gene between mouse Shh-C auto-processing domain and IL-12 (IL-12/Shh-C) was designed in the present study as a self-supporting autocrine system aimed at reducing or eliminating the dependency of NK cells on exogenous IL-2 to sustain their activated status. The data from the present study show that NKIL-12/Shh-C cells have a substantially faster growth rate compared to the NKUN and NKEGFP/Shh-C cells, even in the absence of IL-2. However, IL-12 cannot be the sole driving force for NK cell survival in long-term cultures. The effect of IL-12 was most significant when IL-2 was added at low or medium levels. The NKIL-12/Shh-C cells, when given <10-fold supplementation of IL-2, reached the same growth rate as NKEGFP/Shh-C cells. Also, the Mac-1hi cell population in NKIL-12/Shh-C cells was not significantly higher than that in NKUN cells 7 days after double transduction, suggesting that NKIL-12/Shh-C cells are less mature as a result of their significantly higher proliferation rate. However, after an additional 2 days in culture, the newly divided NK cells reached their maturation stage and the Mac-1hi cell percentage was substantially higher than the NKUN cells. Our results are in agreement with those from previous reports that only DX5+Mac-1low cells in the expansion stage have the potential to be proliferating NK cells. In addition, NKIL-12/Shh-C cells had a significantly lower level of granzyme B expression than that of NKEGFP/Shh-C and NKIL-12 cells, further suggesting that NKIL-12/Shh-C cells were less mature 7 days after double transduction.
When mouse lymphoma YAC-1 cells were used as a target, the cytotoxicities of NKIL-12/Shh-C cells 5 days after double transduction were significantly higher than those of NKUN cells only at E:T ratios of 1:1 and 0.5:1. In addition, 7 days after double transduction, significantly elevated cytotoxicities of both NKIL-12/Shh-C cells were observed compared to NKUN cells at all E:T ratios. Furthermore, NKIL-12/Shh-C cells secreted significantly higher amounts of IFN-γ on the 5th day and even higher on the 7th day than those of NKIL-12 and NKEGFP/Shh-C cells. NK cell cytotoxicity is mediated through 3 different pathways: granule exocytosis pathway, death receptor pathway, and IFN-γ mediated cytotoxicity (31). The present study shows that the enhanced cytotoxicity of NKIL-12/Shh-C cells is mainly due to their increased secretion of cytotoxic cytokines, such as IFN-λ. Although perforin and granzyme B expressions were significantly higher in all lentivirus-transduced NK cells, the expression of these lytic molecules in NKIL-12/Shh-C cells was significantly lower than that in NKIL-12 and NKEGFP/Shh-C cells.
The results from the current study showed that adoptively transferred NK cells effectively localized to lung tissues from mice which had received a tail vein injection of B16 tumor cells 3 days earlier. More NKIL-12/Shh-C cells were accumulated in the lung tissues as indicated by the bigger and brighter fluorescent dots, presumably due to the accumulation of more NKIL-12/Shh-C cells or the increased survival of the accumulated NK cells as a result of locally-accumulated IL-12. Substantially prolonged mice survival and significantly less total weight loss (data not shown) in mice were found following adoptive transfer of NKIL-12/Shh-C cells when compared to mice with NKEGFP/Shh-C cell transfer, even in the absence of IL-2 systemic administration. Plasma cytokine analysis showed that the levels of TNF-α and IFN-λ in the plasma of mice which had received adoptive transfers of NKIL-12/Shh-C cells were significantly higher than those in the plasma of mice which had received NKEGFP/Shh-C or B16 tumor cells. Particularly on day 14 after the adoptive transfers of NK cells, only mice which had received NKIL-12/Shh-C cells showed a detectable level of IFN-γ. It has been suggested that elevated IFN-γ and TNF-α levels are able to promote nitric oxide production to recruit macrophages to the tumor site. IFN-γ was also able to up-regulate MHC class I expression to make target cells more susceptible to T cell-mediated immune response (32). Both IFN-γ and TNF-α have been reported to up-regulate tumor antigen expression, thus making tumors more vulnerable to tumor-infiltrating lymphocyte killing. However, when NK cells were adoptively transferred 10 days after B16 tumor cell injection, very few adoptively transferred NK cells were detected in the deep lung tissue, suggesting that it is very difficult for the adoptively transferred NK cells to penetrate into the tumor mass at this stage. B16 metastases have been documented to be divided into loose and compact types morphologically (8). The compact metastases have several-fold less expression of chemoattractive proteins and they also lack microvascular networks compared to the loose type. These unique features of late tumor tissues may partially explain the inability of NK cells to infiltrate into late tumor tissues.
Local or regional treatment eliminates the systemic adverse reactions caused by soluble cytokines. Previous studies have suggested that the efficiency of the delivery of cytokines into the plasma membrane can be elevated through the reanchoring of GPI-anchored proteins onto neighboring cells (14). With the current strategy, IL-12 with a cholesterol tail would not only anchor to the membrane, but also diffuse into the near vicinity of the producing NK cells to form a concentration gradient. Although the secreted IL-12 level is low, as it can only be detected by ELISA, and not western blot analysis, it should be enough to act on other NK cells or immune cells coming into the gradient range, and would thus have more far reaching effects than just the producing cell alone.
Smyth MJ, Thia KY, Cretney E, et al: Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 162:6658–6662. 1999.PubMed/NCBI
Lauwerys BR, Garot N, Renauld JC and Houssiau FA: Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 165:1847–1853. 2000. View Article : Google Scholar : PubMed/NCBI
Biron CA, Nguyen KB, Pien GC, Cousens LP and Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 17:189–220. 1999. View Article : Google Scholar : PubMed/NCBI
Rosenberg S: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 75:595–603. 1985.PubMed/NCBI
Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L and Perussia B: Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 160:1147–1169. 1984. View Article : Google Scholar : PubMed/NCBI
Goding SR, Yang Q, Knudsen KB, Potter DM and Basse PH: Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells. Hum Gene Ther. 18:701–711. 2007. View Article : Google Scholar : PubMed/NCBI
Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 313:1485–1492. 1985. View Article : Google Scholar
Yang Q, Hokland ME, Bryant JL, et al: Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer. 105:512–519. 2003. View Article : Google Scholar : PubMed/NCBI
Maas RA, Dullens HF and Den Otter W: Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother. 36:141–148. 1993. View Article : Google Scholar : PubMed/NCBI
Imboden M, Shi F, Pugh TD, et al: Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Hum Gene Ther. 14:1037–1048. 2003. View Article : Google Scholar : PubMed/NCBI
Ji J, Li J, Holmes LM, et al: Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma yumor growth in mice. Mol Cancer Ther. 1:1019–1024. 2002.PubMed/NCBI
Konstantinidis KV, Alici E, Aints A, Christensson B, Ljunggren HG and Dilber MS: Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells. Exp Hematol. 33:159–164. 2005. View Article : Google Scholar : PubMed/NCBI
Sanda MG, Restifo NP, Walsh JC, et al: Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst. 87:280–285. 1995. View Article : Google Scholar : PubMed/NCBI
Robertson MJ and Ritz J: Biology and clinical relevance of human natural killer cells. Blood. 76:2421–2438. 1990.PubMed/NCBI
Albertsson PA, Basse PH, Hokland M, et al: NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24:603–609. 2003. View Article : Google Scholar : PubMed/NCBI
Law TM, Motzer RJ, Mazumdar M, et al: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 76:824–832. 1995. View Article : Google Scholar : PubMed/NCBI
Kammula US, White DE and Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 83:797–805. 1998. View Article : Google Scholar : PubMed/NCBI
Skoskiewicz MJ, Colvin RB, Schneeberger EE and Russell PS: Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J Exp Med. 162:1645–1664. 1985. View Article : Google Scholar : PubMed/NCBI